New Zealand markets open in 7 hours 34 minutes

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.2518-0.0305 (-10.80%)
At close: 04:00PM EDT
0.2797 +0.03 (+11.08%)
After hours: 07:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2823
Open0.2957
Bid0.2601 x 1000
Ask0.2518 x 4000
Day's range0.2503 - 0.3079
52-week range0.2080 - 1.9700
Volume964,619
Avg. volume1,361,304
Market cap31.539M
Beta (5Y monthly)2.03
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

    Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5)NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today announced the appointment of Rachelle

  • GlobeNewswire

    uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

    Biotech Executive Brings Extensive Experience Developing Advanced Therapies and Regenerative Medicines Rachelle Jacques Newly elected uniQure board member, Rachelle Jacques LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board’s Audi

  • GlobeNewswire

    Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

    Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through business development continues to be a priorityCash and investments on hand of $114M provides projected runway into first quarter of 2024 Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today prov